Fig. 6.
AAV–follistatin increases muscle strength but does not improve rotarod performance or significantly affect survival. (A and B) Grip strength of hindlimbs (A) and forelimbs (B) were recorded in AAV–GFP- and AAV–follistatin-treated SOD1G93A mice. (C) Latency to fall off the rotarod was measured in AAV–follistatin- AAV–GFP-treated SOD1G93A mice. (D) Survival analysis of AAV–follistatin- and AAV–GFP-treated SOD1G93A mice. AAV–GFP, 126 days; AAV–follistatin, 130 days; P = 0.06 (n = 15; litter-matched; the number of female mice equaled the number of male mice).